MetLife Investment Management’s Sight Sciences SGHT Stock Holding History

MetLife Investment Management’s Portfolio SGHT Stock Details SGHT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$64.7K	Sell	17,166 -1,502	-8%	-$8.11K	﹤0.01%	2652
2025 Q4	$148K	Sell	18,668 -6,510	-26%	-$41.6K	﹤0.01%	2423
2025 Q3	$86.6K	Sell	25,178 -1,859	-7%	-$6.92K	﹤0.01%	2709
2025 Q2	$112K	Buy	+27,037	New	+$90.2K	﹤0.01%	2485
2024 Q4	–	Sell	-21,423	Closed	-$135K	–	2852
2024 Q3	$135K	Hold	21,423	–	–	﹤0.01%	2492
2024 Q2	$143K	Buy	+21,423	New	+$127K	﹤0.01%	2434
2023 Q3	–	Sell	-12,216	Closed	-$101K	–	2970
2023 Q2	$101K	Hold	12,216	–	–	﹤0.01%	2675
2023 Q1	$107K	Hold	12,216	–	–	﹤0.01%	2521
2022 Q4	$149K	Buy	+12,216	New	+$116K	﹤0.01%	2417
2022 Q3	–	Sell	-14,364	Closed	-$129K	–	2832
2022 Q2	$129K	Hold	14,364	–	–	﹤0.01%	2591
2022 Q1	$166K	Buy	+14,364	New	+$221K	﹤0.01%	2465
2021 Q4	–	Sell	-4,737	Closed	-$108K	–	2547
2021 Q3	$108K	Buy	+4,737	New	+$156K	﹤0.01%	2414

Other funds holding SGHT

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return

Americana Partners Houston, Texas $3.85B AUM 23.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BGI

B Group Inc Dallas, Texas $135M AUM 80% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

MetLife Investment Management's SGHT Position: Q1 2026 in Review

MetLife Investment Management reduced its Sight Sciences (SGHT) stake by 8% in Q1 2026, selling an estimated $8.11K and leaving 17,166 shares worth $64.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2652.

MetLife Investment Management first reported a position in SGHT in Q3 2021 and has held it in 12 quarters since. The position peaked at $166K in Q1 2022. 114 funds tracked by Wall St. Rank hold SGHT as of Q1 2026.

MetLife Investment Management held 17,166 shares of Sight Sciences worth $64.7K as of Q1 2026.
MetLife Investment Management sold 1,502 Sight Sciences shares in Q1 2026, an estimated $8.11K.
Sight Sciences made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #2652 holding.
MetLife Investment Management first reported a position in Sight Sciences in Q3 2021 and has held it in 12 quarters since.
MetLife Investment Management's Sight Sciences position peaked at $166K in Q1 2022.
114 funds tracked by Wall St. Rank held Sight Sciences as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.